About GondolaBio
GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Who You Are
You are a translational medicine scientist operating at the interface of discovery and early clinical development, with expertise in biomarker strategy, assay development, and clinical implementation. You bring a strong scientific foundation in biomarker biology and assay technologies, experience working within CLIA-certified or regulated laboratory environments, and the ability to operate cross-functionally across discovery, clinical development, and clinical operations. You are execution-oriented, capable of driving work through CROs and external partners, and thrive in a fast-paced biotech environment. Experience in neurology or CNS disorders is preferred but not required.
Role Overview
This role will partner with the Translational Medicine VP to drive clinical biomarker strategy and execution across GondolaBio’s early neuroscience clinical programs. The individual will be responsible for translating discovery stage hypotheses into clinically actionable biomarker approaches, ensuring assays are fit-for purpose, validated, and operationally feasible in global studies. This role will directly impact how target engagement, pharmacodynamic effects, and disease biology are measured in patients.
Key Responsibilities
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.